Neoplasms

All Conditions

Rare Diseases

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

All Drugs and Chemicals

Immunomodulating Agents

Patients, ≥18 years of age, with newly diagnosed GBM, World Health Organization (WHO) Grade IV, undergoing gross total resection (defined as \>90% of contrast enhancing volume removed on post-operative MRI) and collection of blood, bone marrow, and tumor.

Tumor collection (\> 1cm3): Intraoperatively

Peripheral blood collection:

* Intraoperatively (60mL)
* Post-resection (30mL)
* Post- standard of care treatment (30mL)

Bone marrow aspiration:

* Intraoperatively (10mL)
* Post-resection (5mL)
* Post- standard of care treatment (5mL)

Biorepository

Peter Fecci, M.D., Ph.D.

Beth Mancuso-Mills, M.B.A.

Beth Perry, RN

Claudia E Pamanes, MPH

The main goal of this study is to provide foundational data to drive translational approaches for an entirely novel category of immunotherapy.

The investigators' recent studies show that large numbers of T cells in patients and mice with intracranial tumors are sequestered in bone marrow. This phenomenon mysteriously confines a pool of functional, naïve T cells with anti-tumor capacity to a compartment where they are unable to access tumor, eliciting a mode of T cell dysfunction categorized as "ignorance." The investigators have uncovered that loss of the sphingosine-1-phosphate receptor 1 (S1P1) from the surface of T cells mediates their sequestration in bone marrow, while blocking internalization of S1P1 facilitates stabilization of the receptor on T cells and frees them for anti-tumor activities. As the investigators look to design interventions targeting β-arrestin mediated S1P1 internalization as a novel anti-tumor strategy, they need to better understand variations in sequestration across patients, over time, and with treatment. Assessing these variations and biomarkers that may accompany them will help to establish a target treatment population, as well as the optimal timing for intervention.

Primary Objectives:

1. Assess variations in blood and bone marrow T cell counts as they relate to treatment time-points in patients with glioblastoma (GBM).
2. Assess variations in S1P1 levels and their correlation with blood and bone marrow T cell counts over the course of treatment in patients with GBM

Exploratory Objectives:

1. Assess the associations between tumor size and degree of lymphopenia and bone marrow T cell sequestration observed.
2. Compare The Cancer Genome Atlas (TCGA) subclasses with respect to the degree of lymphopenia and bone marrow T cell sequestration observed at diagnosis.
3. Examine patient plasma, tumor supernatant, and tumor ribonucleic acid (RNA) for markers that are associated with lymphopenia, T cell S1P1 levels, and bone marrow T cell sequestration. Initial candidates will include transforming growth factor-β (TGFβ) 1/2, tumor necrosis factor (TNF), interleukin (IL)-33, IL-6, catecholamines, signal transducer and activator of transcription 3 (STAT3) RNA, and Kruppel-like factor 2 (KLF2) RNA.
4. Compare T cell phenotypes in the blood and bone marrow of patients exhibiting versus not exhibiting T cell lymphopenia or sequestration.
5. Compare differences in tumor-infiltrating lymphocyte numbers and phenotypes between patients with and without lymphopenia / sequestration at diagnosis.
6. Establish baseline β-arrestin 1 and 2 expression in patients and assess variation across individuals.
7. Archive samples for subsequent assessment of β-arrestin recruitment to the cytoplasmic component of T cell S1P1, as well as the capacity to inhibit such recruitment in vitro with candidate small molecules.

1. Tumor collection
2. Peripheral blood sample collection
3. Bone marrow aspiration

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma

Assess variations in blood and bone marrow T cell counts as they relate to treatment time-points in patients with glioblastoma.

Assess variations in S1P1 levels and their correlation with blood and bone marrow T cell counts over the course of treatment in patients with glioblastoma.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	NCT04657146	Glioblastoma	Biorepository	18 Years -	Duke University
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	NCT04657146	Glioblastoma	Biorepository	18 Years -	Duke University
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	NCT04657146	Glioblastoma	Biorepository	18 Years -	Duke University

Spots Global Cancer Trial Database for glioblastoma, t cells, sequestration